Clinical Trials
18 trialsNCT04248829 2024-12-03
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Phase 3 Active not recruiting
NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed
NCT03486496 2018-04-03
Geber
Fujian Cancer Hospital
Phase 2 Unknown
NCT00310154 2017-05-30
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT02282267 2017-02-24
Benefit
Peking University Cancer Hospital & Institute
Phase NA Unknown
NCT02787447 2016-11-25
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT02951637 2016-11-01
Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
Shanghai Chest Hospital
Phase 2 Unknown
NCT02788058 2016-06-02
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT00049543 2015-01-01
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01024712 2013-08-12
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00955695 2013-08-02
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00040794 2013-06-05
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00411047 2013-05-14
Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00268255 2013-04-16
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Withdrawn
NCT00020709 2013-02-27
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01502202 2012-06-20
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
National Cancer Center, Korea
Phase 2 Unknown
NCT00217698 2012-06-05
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT00616499 2009-02-09
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown